Skip to content

Study · Systematic review · 2025

6 results

Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.

Awad AA, Abdrabou Abouelmagd A, Mohammed F, Elettreby AM, Mahmoud Marey M, Aldemerdash MA, Soliman SM, Belal MM, Abosheaishaa H

Proceedings (Baylor University. Medical Center)1 Apr 2025Cited by 1 (Europe PMC)

PMID40557198 (opens in a new tab)PMCIDPMC12184113 (opens in a new tab)DOI10.1080/08998280.2025.2480512 (opens in a new tab)PepBankPUB-40557198
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in obesity, survodutide significantly reduced relative body weight (SMD -1.5).

    In plain wordsIn a pooled analysis of trials in people with obesity, survodutide lowered relative body weight.

    Peptide
    Survodutide
    Outcome
    DecreaseRelative body weight reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    SMD
    −1.5 SMD
    relative body weight

    Source sentences

    Summary
    There was a significant relative body weight reduction in the survodutide group (SMD: -1.5; 95% CI: -2.05 to -0.95; P < 0.00001).
    1 context sentence
    Summary · context
    We searched PubMed, Web of Science, Scopus, and Cochrane Library databases until May 2024 for randomized controlled trials using survodutide obesity treatment.
  2. 02HumanSystematic reviewSafety outcome

    In four included trials, overall adverse events did not differ significantly between survodutide and placebo (RR 1.18).

    In plain wordsIn four pooled trials, overall side effects were not significantly different between survodutide and placebo.

    Peptide
    Survodutide
    Outcome
    No significant changeOverall adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    RR
    1.18
    overall adverse events

    Source sentences

    Summary
    Overall adverse events in the four included studies weren't significantly different between the survodutide group and placebo group (RR: 1.18; 95% CI: 0.98 to 1.41; I 2 = 72%; P = 0.08).
    1 context sentence
    Summary · context
    We searched PubMed, Web of Science, Scopus, and Cochrane Library databases until May 2024 for randomized controlled trials using survodutide obesity treatment.
  3. 03HumanSystematic reviewSafety outcome

    In four included trials, survodutide was associated with a higher risk of diarrhea than placebo (RR 1.89).

    In plain wordsIn four pooled trials, diarrhea was more likely with survodutide than with placebo.

    Peptide
    Survodutide
    Outcome
    IncreaseDiarrhea
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    RR
    1.89
    diarrhea

    Source sentences

    Summary
    Survodutide was associated with a higher risk of developing diarrhea than the placebo group in the four included trials (RR: 1.89; 95% CI: 1.2 to 2.97; I 2=0%; P < 0.00001).
    1 context sentence
    Summary · context
    We searched PubMed, Web of Science, Scopus, and Cochrane Library databases until May 2024 for randomized controlled trials using survodutide obesity treatment.
  4. 04HumanSystematic reviewEfficacy outcome

    In the meta-analysis, survodutide reduced hemoglobin A1c (P < 0.00001).

    In plain wordsIn a pooled analysis of trials, survodutide lowered hemoglobin A1c, a measure of blood sugar control.

    Peptide
    Survodutide
    Outcome
    DecreaseHemoglobin A1c
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Survodutide effectively reduced relative body weight, absolute body weight, and hemoglobin A1c (P < 0.00001).
    1 context sentence
    Summary · context
    We searched PubMed, Web of Science, Scopus, and Cochrane Library databases until May 2024 for randomized controlled trials using survodutide obesity treatment.
  5. 05HumanSystematic reviewEfficacy outcome

    In the meta-analysis, survodutide reduced absolute body weight (P < 0.00001).

    In plain wordsIn a pooled analysis of trials, survodutide lowered absolute body weight.

    Peptide
    Survodutide
    Outcome
    DecreaseAbsolute body weight reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Survodutide effectively reduced relative body weight, absolute body weight, and hemoglobin A1c (P < 0.00001).
    1 context sentence
    Summary · context
    We searched PubMed, Web of Science, Scopus, and Cochrane Library databases until May 2024 for randomized controlled trials using survodutide obesity treatment.
  6. 06HumanSystematic reviewSafety outcome

    In the meta-analysis of randomized trials in obesity, gastrointestinal adverse events were higher in the survodutide group than in the placebo group.

    In plain wordsIn pooled trials in people with obesity, stomach and bowel side effects were more common with survodutide than with placebo.

    Peptide
    Survodutide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    gastrointestinal adverse events were higher in the survodutide group

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.